PEAR Therapeutics is the leader in FDA-cleared prescription digital therapeutics. The company's approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. PEAR's lead product, reSET, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. PEAR's product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive order, and insomnia, for which PEAR intends to obtain FDA clearance.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/02/18 | $50,000,000 | Series B |
5AM Ventures Arboretum Ventures Bridge Builders Collaborative EDBI Jazz Venture Partners Novartis Venture Funds Temasek  | undisclosed |
| 01/04/19 | $64,000,000 | Series C |
5AM Ventures Arboretum Ventures Blue Water Life Science Fund Bridge Builders Collaborative EDBI Jazz Venture Partners Novartis Venture Funds Temasek Trustbridge Partners | undisclosed |
| 12/10/20 | $80,000,000 | Series D |
5AM Ventures Arboretum Ventures CrimsoNox Capital EDBI Forth Management Jazz Venture Partners Novartis Pilot House Ventures Sarissa Capital Shanda Group SoftBank Vision Fund 2 Temasek | undisclosed |
